The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase) for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). This decision, announced November 5, 2026, targets patients whose disease has progressed following platinum-based chemotherapy and immunotherapy, addressing a decade-long gap in new treatment options.
Accelerated Approval for Refractory HNSCC
The FDA’s regulatory action centers on a patient population with historically poor outcomes and limited therapeutic alternatives. As noted in the agency’s official announcement, the approval specifically excludes patients with oropharyngeal squamous cell carcinoma associated with human papillomavirus (HPV). Rybrevant Faspro, a subcutaneous bispecific antibody, functions by targeting both EGF (epidermal growth factor) and MET receptors. These receptors are frequently overexpressed in up to 90% of recurrent and metastatic HNSCC cases, contributing to disease progression and resistance.
According to Medscape, the approval is based on findings from the OrigAMI-4 trial, a single-arm, open-label study involving 102 patients. The trial demonstrated an overall response rate (ORR) of 42%, with 15% of participants achieving a complete response. Notably, 56% of those who responded maintained that response for six months or longer. These results contrast with currently available therapies for this setting, which typically yield an ORR of 20% or less.
Clinical Insights for Patients
- Targeted Approach: The drug works by blocking two specific pathways (EGFR and MET) that cancer cells use to grow and survive.
- Administration: It is delivered via a subcutaneous injection (under the skin) once every three weeks, based on the patient’s body weight.
- Requirement for Further Data: Because this is an accelerated approval based on early indicators like tumor response, the manufacturer is required to conduct confirmatory studies, such as the ongoing OrigAMI-5 trial, to verify long-term clinical benefits.
OrigAMI-4 Trial Reveals High Response Rate and Severe Adverse Reactions
While the OrigAMI-4 trial results show an overall response rate of 42% compared to approximately 20% or less for currently approved therapies, the safety profile includes notable adverse reactions that necessitate clinical monitoring. The most frequently observed adverse reactions included rash (79%), fatigue (39%), nail toxicity (35%), stomatitis (32%), and edema (28%).
@FDA has granted accelerated approval to @JNJNews RYBREVANT FASPRO for adults with recurrent or metastatic head and neck cancer. 🔗 Read more: https://t.co/1HQjQh76jz#FDA #JohnsonAndJohnson #RYBREVANTFASPRO #CancerTreatment #Oncology #MededgeMEA pic.twitter.com/MbyOfW1Nhg
Serious adverse reactions were reported, including pneumonia (8%), hemorrhage (4.9%), and interstitial lung disease (ILD) or pneumonitis (2%). The FDA reported that 6% of patients in the trial died from adverse reactions, including instances of sudden death, myocardial ischemia, tumor hemorrhage, and aspiration pneumonia.
| Adverse Reaction | Incidence in OrigAMI-4 (%) |
|---|---|
| Rash | 79% |
| Fatigue | 39% |
| Nail Toxicity | 35% |
| Stomatitis | 32% |
| Edema | 28% |
Monitor for Pulmonary Distress and Severe Reactions
The prescribing information for Rybrevant Faspro includes specific warnings regarding hypersensitivity and administration-related reactions. Patients and caregivers must be alert to signs of pulmonary distress, such as new or worsening dyspnea (shortness of breath), cough, or fever, which may indicate ILD or pneumonitis. Ocular toxicity and dermatologic reactions are also common; patients should report any changes in vision or significant skin irritation to their oncology provider immediately. The drug carries a warning for fetal toxicity, necessitating strict contraceptive measures for those of reproductive potential.
FDA Grants Breakthrough Therapy Designation for Limited Treatment Options
Angelo De Claro, M.D., director of the FDA’s Oncology Center of Excellence, stated that the approval represents a meaningful step forward for a disease where options have historically been limited. The FDA granted the therapy Breakthrough Therapy designation, reflecting the urgent need for new interventions after patients have received platinum-based chemotherapy and immunotherapy. While this approval offers a new path, the medical community continues to evaluate how EGFR and MET pathway alterations can be used to better identify which patients are most likely to respond, as routine precision selection remains an evolving field.
The manufacturer, Johnson & Johnson, is currently conducting the OrigAMI-5 trial, a Phase 3 study investigating the drug in the first-line setting.
$JNJ just got U. S. FDA approval for RYBREVANT FASPRO, the first and only dual-targeted therapy for advanced head and neck cancer. pic.twitter.com/AymzVc6I8m
References
More on Drug Administration
🚨 $JNJ WINS ACCELERATED FDA APPROVAL FOR RYBREVANT FASPRO IN ADVANCED HEAD AND NECK CANCER // First dual targeted therapy in the setting, on a 42 percent response rate Johnson & Johnson $JNJ said tonight the FDA granted accelerated approval to RYBREVANT FASPRO, its subcutaneous… pic.twitter.com/xQw210XJBm
🚨💊 FDA granted accelerated approval to Janssen's (JNJ) Rybrevant Faspro for recurrent/metastatic HNSCC after platinum chemo and immunotherapy. Trial ORR 42% vs ~20% for approved options. FDA: https://t.co/soDcXoQOWA
🇺🇸 The FDA has approved a new Johnson & Johnson treatment for advanced head and neck cancer after clinical trials showed tumors shrinking or disappearing in 42% of patients. The drug, Rybrevant Faspro, is intended for certain patients whose cancer has continued spreading or… pic.twitter.com/QP6WWsmf72
